Characteristics, risk factors and outcomes of adult cancer patients with extensively drug-resistant Pseudomonas aeruginosa infections

Infection

Volumn 42, Issue 4, 2014, Pages 721-728

  Samonis, G ^a   Vardakas, K Z ^b,c   Kofteridis, D P ^a   Dimopoulou, D ^a   Andrianaki, A M ^a   Chatzinikolaou, I ^c   Katsanevaki, E ^d   Maraki, S ^e   Falagas, M E ^b,c,f  

^a UNIVERSITY OF CRETE   (Greece)

^b ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^c IASO GENERAL HOSPITAL   (Greece)

^d NATIONAL TECHNICAL UNIVERSITY OF ATHENS   (Greece)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Appropriate empirical treatment; Bacteremia; Gram negative; Malignancy; Neutropenia; Pneumonia

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLINDAMYCIN; COLISTIN; CORTICOSTEROID; DAPTOMYCIN; FOSFOMYCIN; GRANULOCYTE COLONY STIMULATING FACTOR; LINEZOLID; METRONIDAZOLE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE; ANTIINFECTIVE AGENT;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; BACTERIAL PNEUMONIA; BACTERIUM ISOLATION; CANCER MORTALITY; CANCER PATIENT; CATHETER INFECTION; CAUSE OF DEATH; CENTRAL VENOUS CATHETER; COHORT ANALYSIS; EXTENSIVELY DRUG RESISTANT PSEUDOMONAS AERUGINOSA INFECTION; FEMALE; GREECE; GROUPS BY AGE; HEMATOLOGIC MALIGNANCY; HUMAN; INFECTION RISK; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTINATIONAL ASSOCIATION FOR SUPPORTIVE CARE IN CANCER RISK INDEX; NEUTROPENIA; OUTCOME ASSESSMENT; POLYPHARMACY; PREDICTIVE VALUE; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; SKIN INFECTION; SOFT TISSUE INFECTION; SOLID TUMOR; URINARY TRACT INFECTION; VERY ELDERLY; COMPLICATION; DRUG EFFECTS; MICROBIOLOGY; MIDDLE AGED; NEOPLASM; PSEUDOMONAS INFECTIONS; RISK FACTOR; SURVIVAL; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; COHORT STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; GREECE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84906936024     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-014-0635-z     Document Type: Article

References (40)

1. Fortaleza CM, Figueiredo LC, Beraldo CC, Melo EC, Pola PM, Aragao VD. Risk factors of oropharyngeal carriage of Pseudomonas aeruginosa among patients from a Medical-Surgical Intensive Care Unit. Braz J Infect Dis. 2009;13:173-6.
2. Cheong HS, Kang CI, Wi YM, et al. Clinical significance and predictors of community-onset Pseudomonas aeruginosa bacteremia. Am J Med. 2008;121:709-14.
3. Iversen BG, Brantsaeter AB, Aavitsland P. Nationwide study of invasive Pseudomonas aeruginosa infection in Norway: importance of underlying disease. J Infect. 2008;57:139-46.
4. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med. 2000;160:501-9. (Pubitemid 30112273)
5. Gonzalez-Barca E, Fernandez-Sevilla A, Carratala J, Granena A, Gudiol F. Prospective study of 288 episodes of bacteremia in neutropenic cancer patients in a single institution. Eur J Clin Microbiol Infect Dis. 1996;15:291-6. (Pubitemid 26159689)
6. Cherif H, Kronvall G, Bjorkholm M, Kalin M. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J. 2003;4:420-6. (Pubitemid 38088787)
7. Parkins MD, Gregson DB, Pitout JD, Ross T, Laupland KB. Population-based study of the epidemiology and the risk factors for Pseudomonas aeruginosa bloodstream infection. Infection. 2010;38:25-32.
8. Arvanitidou M, Katikaridou E, Douboyas J, Tsakris A. Epidemiological characteristics of nosocomial bacteraemias among ICU and non-ICU patients in a tertiary-care hospital in Greece. J Hosp Infect. 2005;59:70-2. (Pubitemid 39618970)
9. Samonis G, Vardakas KZ, Maraki S, et al. A prospective study of characteristics and outcomes of bacteremia in patients with solid organ or hematologic malignancies. Support Care Cancer. 2013;21:2521-6.
10. Falagas ME, Rafailidis PI, Matthaiou DK, Virtzili S, Nikita D, Michalopoulos A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int J Antimicrob Agents. 2008;32:450-4.
11. Tam VH, Rogers CA, Chang KT, Weston JS, Caeiro JP, Garey KW. Impact of multidrug-resistant Pseudomonas aeruginosa bacteremia on patient outcomes. Antimicrob Agents Chemother. 2010;54:3717-22.
12. Vardakas KZ, Rafailidis PI, Konstantelias AA, Falagas ME. Predictors of mortality in patients with infections due to multidrug resistant Gram negative bacteria: the study, the patient, the bug or the drug? J Infect. 2013;66:401-14.
13. Accessed at http://www.strobe-statement.org/fileadmin/Strobe/uploads/ checklists/STROBE-checklist-v4-combined.pdf.
14. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18:268-81.
15. Horino T, Chiba A, Kawano S, et al. Clinical characteristics and risk factors for mortality in patients with bacteremia caused by Pseudomonas aeruginosa. Intern Med. 2012;51:59-64.
16. Krcmery V, Koprnova J, Gogova M, Grey E, Korcova J. Pseudomonas aeruginosa bacteraemia in cancer patients. J Infect. 2006;52:461-3. (Pubitemid 43811963)
17. Joo EJ, Kang CI, Ha YE, et al. Clinical predictors of Pseudomonas aeruginosa bacteremia among Gram-negative bacterial infections in non-neutropenic patients with solid tumor. J Infect. 2011;63:207-14.
18. Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005;104:205-12. (Pubitemid 40847770)
19. Falagas ME, Kopterides P. Risk factors for the isolation of multi-drug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: a systematic review of the literature. J Hosp Infect. 2006;64:7-15. (Pubitemid 44161380)
20. Park YS, Lee H, Chin BS, et al. Acquisition of extensive drug-resistant Pseudomonas aeruginosa among hospitalized patients: risk factors and resistance mechanisms to carbapenems. J Hosp Infect. 2011;79:54-8.
21. Falagas ME, Koletsi PK, Kopterides P, Michalopoulos A. Risk factors for isolation of strains susceptible only to polymyxin among patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother. 2006;50:2541-3. (Pubitemid 43993200)
22. Kasiakou SK, Michalopoulos A, Soteriades ES, Samonis G, Sermaides GJ, Falagas ME. Combination therapy with intravenous colistin for management of infections due to multidrug-resistant Gram-negative bacteria in patients without cystic fibrosis. Antimicrob Agents Chemother. 2005;49:3136-46. (Pubitemid 41060551)
23. Mastoraki A, Douka E, Kriaras I, Stravopodis G, Manoli H, Geroulanos S. Pseudomonas aeruginosa susceptible only to colistin in intensive care unit patients. Surg Infect (Larchmt). 2008;9:153-60. (Pubitemid 351563818)
24. Durakovic N, Radojcic V, Boban A, et al. Efficacy and safety of colistin in the treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in patients with hematologic malignancy: a matched pair analysis. Intern Med. 2011;50:1009-13.
25. Hachem RY, Chemaly RF, Ahmar CA, et al. Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients. Antimicrob Agents Chemother. 2007;51:1905-11. (Pubitemid 46903072)
26. Micek ST, Lloyd AE, Ritchie DJ, Reichley RM, Fraser VJ, Kollef MH. Pseudomonas aeruginosa bloodstream infection: importance of appropriate initial antimicrobial treatment. Antimicrob Agents Chemother. 2005;49:1306-11. (Pubitemid 40463352)
27. McGregor JC, Rich SE, Harris AD, et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis. 2007;45:329-37. (Pubitemid 47101029)
28. Giamarellou H. Aminoglycosides plus beta-lactams against gram-negative organisms. Evaluation of in vitro synergy and chemical interactions. Am J Med. 1986;80:126-37. (Pubitemid 16036777)
29. Giamarellou H, Zissis NP, Tagari G, Bouzos J. In vitro synergistic activities of aminoglycosides and new beta-lactams against multiresistant Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984;25:534-6. (Pubitemid 14129626)
30. Bliziotis IA, Petrosillo N, Michalopoulos A, Samonis G, Falagas ME. Impact of definitive therapy with beta-lactam monotherapy or combination with an aminoglycoside or a quinolone for Pseudomonas aeruginosa bacteremia. PLoS One. 2011;6:e26470.
31. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med. 1989;87:540-6. (Pubitemid 19274758)
32. Garnacho-Montero J, Sa-Borges M, Sole-Violan J, et al. Optimal management therapy for Pseudomonas aeruginosa ventilator-associated pneumonia: an observational, multicenter study comparing monotherapy with combination antibiotic therapy. Crit Care Med. 2007;35:1888-95. (Pubitemid 47220363)
33. Kumar A, Zarychanski R, Light B, et al. Early combination antibiotic therapy yields improved survival compared with monotherapy in septic shock: a propensity-matched analysis. Crit Care Med. 2010;38:1773-85.
34. Leibovici L, Paul M, Poznanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother. 1997;41:1127-33. (Pubitemid 27194197)
35. Vardakas KZ, Tansarli GS, Bliziotis IA, Falagas ME. beta-Lactam plus aminoglycoside or fluoroquinolone combination versus beta-lactam monotherapy for Pseudomonas aeruginosa infections: a meta-analysis. Int J Antimicrob Agents. 2013;41:301-10.
36. Kumar A, Safdar N, Kethireddy S, Chateau D. A survival benefit of combination antibiotic therapy for serious infections associated with sepsis and septic shock is contingent only on the risk of death: a meta-analytic/meta- regression study. Crit Care Med. 2010;38:1651-64.
37. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. BMJ. 2004;328:668.
38. Paul M, Soares-Weiser K, Leibovici L. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for fever with neutropenia: systematic review and meta-analysis. BMJ. 2003;326:1111.
39. Falagas ME, Tansarli GS, Ikawa K, Vardakas KZ. Clinical outcomes with extended or continuous versus short-term intravenous infusion of carbapenems and piperacillin/tazobactam: a systematic review and meta-analysis. Clin Infect Dis. 2013;56:272-82.
40. Falagas ME, Tansarli GS, Rafailidis PI, Kapaskelis A, Vardakas KZ. Impact of antibiotic MIC on infection outcome in patients with susceptible Gram-negative bacteria: a systematic review and meta-analysis. Antimicrob Agents Chemother. 2012;56:4214-22.